Page 80 - 71_01
P. 80
MARÍA CASCALES ANGOSTO AN. R. ACAD. NAC. FARM.
(43) AMIT, S.; BEN-NERIAH, Y. (2003). NF-kappaB activation in cancer: a challenge
for ubiquitination- and proteasome-based therapeutic approach. Semin Can-
(44) cer Biol 13, 15-28.
(45) CIECHANOVER, A. & IWAI, K. (2004). The ubiquitin system: from basic mecha-
nisms to the patient bed. IUBMB Life 56, 193-201.
(46) CIECHANOVER, A. (2003). The ubiquitin proteolytic system and pathogenesis of
(47) human diseases: a novel platform for mechanism-based drug targeting. Bio-
chem Soc Trans. 31, 74-81.
(48) CASCALES, M. (1999). Oxidación y degradación de proteínas. En: Estrés oxida-
tivo, envejecimiento y enfermedad. Instituto de España. Madrid, pp. 91-123.
(49) CIECHANOVER, A.; BRUNDIN, P. (2003). The ubiquitin proteasome system in neu-
(50) rodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron.
40, 427-446.
CHOI, P.; OSTREROVA-GOLTS, N.; SPARKMAN, D.; COCHRAN, E.; LEE, J. M.; WOLOZIN,
B. (2000). Parkin is metabolized by the ubiquitin/proteosome system. Neuro-
report 11, 2635-2638.
MILLER, R. J.; WILSON, S. M. (2003). Neurological disease: UPS stops delive-
ring! Trends Pharmacol Sci. 24, 18-23.
ADAMS, J. (2002). Proteasome inhibition: a novel approach to cancer therapy.
Trends Mol Med. 8 (4 Suppl): S49-S54.
82
